Skip to main content
. 2025 Oct 3;104(40):e44700. doi: 10.1097/MD.0000000000044700

Figure 5.

Figure 5.

Trends in nivolumab and pembrolizumab-induced hepatic autoimmune disorders (2014–2024). CI = confidence interval, IC = information component.